SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Aurobindo Pharma soars as its arm gets EIR for Telangana unit

20 Mar 2026 Evaluate

Aurobindo Pharma is currently trading at Rs. 1281.90, up by 33.95 points or 2.72% from its previous closing of Rs. 1247.95 on the BSE.

The scrip opened at Rs. 1252.35 and has touched a high and low of Rs. 1287.50 and Rs. 1252.35 respectively. So far 15678 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1319.60 on 12-Mar-2026 and a 52 week low of Rs. 994.35 on 07-Apr-2025.

Last one week high and low of the scrip stood at Rs. 1314.85 and Rs. 1240.40 respectively. The current market cap of the company is Rs. 74586.54 crore.

The promoters holding in the company stood at 51.82%, while Institutions and Non-Institutions held 41.63% and 6.56% respectively. 

Aurobindo Pharma’s wholly owned subsidiary -- Apitoria Pharma has received Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for its Unit-V, an API manufacturing facility situated at Telangana. The USFDA has classified the said facility as Voluntary Action Indicated (VAI) and this inspection is now closed.

The USFDA had conducted an inspection of the said facility from December 01 to December 12, 2025 and issued a ‘Form 483’ with 03 observations.

Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.

Aurobindo Pharma Share Price

1389.55 -6.95 (-0.50%)
30-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1808.20
Dr. Reddys Lab 1322.95
Cipla 1309.90
Zydus Lifesciences 891.65
Lupin 2303.70
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×